BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Patients with Ovarian Cancer

BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Patients with Ovarian Cancer

Source: 
CP Wire
snippet: 

BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced on 5/17/18 that the first patient has been enrolled in a Phase 3 clinical trial in China of pamiparib (BGB-290), an investigational PARP inhibitor, in patients with platinum-sensitive recurrent ovarian cancer.